Box is headquartered in Redwood City, CA, with offices across the United States, Europe, and Asia. Founded in 2005, Box simplifies work for leading global organizations, including AstraZeneca, JLL, and Nationwide. For more on Box for LifeSciences, visit box.com/industries/life-sciences-biotech.īox (NYSE:BOX) is the leading Content Cloud, a single platform that empowers organizations to manage the entire content lifecycle, work securely from anywhere, and integrate across best-of-breed apps. With today’s announcement, Clario joins a growing list of leading life science and biotechnology organizations leveraging Box to power new ways of working, including AstraZeneca, Amgen, and Allergan.
Power the company’s post-merger consolidation, as the two separate enterprises come together with Box as a common content layerīox first announced GxP Validation in 2018 as an innovative approach for maintaining GxP compliance in the cloud. Leverage Box APIs to enhance and innovate client-facing portalsĮxpand on efficiencies through custom automations and workflow Protect the company’s most critical data with heightened security Power internal and external collaboration across the global organization Manage and centalize both unregulated and regulated content in the cloud with Box GxP Validation
#Clario bioclinica trial
“Clario is leading the way in clinical trial technology that will transform patients’ lives,” said Manu Vohra, Managing Director, Global Life Sciences at Box “We’re incredibly excited that Box is playing a central role as Clario moves forward, powering GxP use cases across the merged organization and helping consolidate 12 different content management systems into one.”Ĭlario is utilizing the Box Content Cloud to: “It is crucial to maintain the highest quality across every aspect of our work, and for that reason we have standardized all regulated and unregulated content using Box as our single validated, secure platform.” “Clario generates rich clinical evidence by fusing scientific expertise and global scale with a groundbreaking endpoint technology platform, minimizing risk in clinical trials around the globe,” said Jay Ferro, Clario’s Chief Technology & Information Officer. Most recently in 2021, ERT and Bioclinica, two leading clinical research data management technology companies, merged to become Clario. Since its inception in 1972, the company has grown through the acquisition of cutting-edge biotechnology enterprises. Between 20 alone, the company supported 70% of all FDA approvals. Over the last 30 years, Clario has completed more than 19,000 clinical trials and has contributed to 870 regulatory approvals. Clario, a leading clinical trial data management company, has already deployed Box to 2,600 employees to power secure collaboration.Ĭlario delivers leading endpoint technology solutions for decentralized (DCT), hybrid and site-based clinical trials. (NYSE: BOX), the leading Content Cloud, today announced that Clario has chosen Box as its single, integrated solution to centralize regulated and unregulated content in the cloud. Learn more about the integration of ERT and Bioclinica by visiting the dedicated merger webpage.Box, Inc. Joe Eazor is the CEO of the merged company, and the management team will be composed of a combination of both ERT and Bioclinica executives.
This will enable us to be more capable partners to our customers, and, more importantly, enhance our ability to help improve health and save lives.” “Our newly combined organization delivers on our commitment to accelerate innovation for today’s complex and fast-moving clinical trials environment.
“Together, as we plan our exciting future, our top priorities are ensuring our current services continue without interruption or change, and to listening closely to our customers to better serve their needs. “We are excited to welcome Bioclinica and look forward to delivering even greater clinical trial success for our customers through our expanded integrated offerings and innovation roadmap,” said Joe Eazor, President and CEO of ERT. This integrated approach will improve the clinical trial experience for sites, customers, and patients. Together, the combined company is committed to accelerating market-leading investments in research and development to bring more integrated endpoint technology and provide access to a broader team of medical and scientific industry leaders. By joining forces, ERT strengthens the most comprehensive and robust endpoint data collection portfolio in the industry with greater integrated and digital solutions across essential endpoints - including imaging, respiratory, cardiac, eCOA with connected devices, as well as precision motion.
#Clario bioclinica software
The transaction combines Bioclinica’s expertise in imaging, eClinical software and drug safety solutions with ERT’s expertise in eCOA, cardiac safety, respiratory and wearables.
0 kommentar(er)
